NCT06714097View on ClinicalTrials.gov

Application of Digital Twins' Technology in Patients Who Had a Stroke, with Moyamoya Disease and with Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: a Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project)

NANot yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2026

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
StrokeMoyamoya DiseaseCerebral Amyloid Angiopathy
Interventions
DEVICE

AI

STRATIF-AI apps will be used as an integral part of the dialogue with patients during thesecondary prevention phase

OTHER

healthy dialogue

Patients allocated to arm 2 will receive only standard secondary prevention, which includes typical treatments and monitoring protocols used for patients with stroke, Moyamoya disease, and CAA

Trial Locations (1)

20133

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan

All Listed Sponsors
lead

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

OTHER

NCT06714097 - Application of Digital Twins' Technology in Patients Who Had a Stroke, with Moyamoya Disease and with Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: a Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project) | Biotech Hunter | Biotech Hunter